Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27197
IPSCIO Record ID: 27226
LED allows cancer Phase I Breast, Prostate, 2 Patents patients to tolerate higher completed, Hematological dosages of chemotherapy initiated providing greater therapeutic Phase II in value in a number of types of June 1998 cancer tumors; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs. This membrane encapsulation feature of liposome enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug – clinical trial. Pursuant to the license agreement, the Licensee agreed to assume all further responsibility for, and the costs associated with, the further development and testing of LED and LEP and the obtaining of all regulatory approvals.
IPSCIO Record ID: 993
IPSCIO Record ID: 28952
Camptothecin is a cytotoxic quinoline alkaloid discovered in the screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine, showing anticancer activity in preliminary clinical trials but also low solubility and (high) adverse drug reaction. CPT analogues have been approved and are used in cancer chemotherapy.
The license is for the rights to deliver paclitaxel or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets.
The methods, composition, and information claimed in U.S. Patent No. 5,049,388, entitled Small Particle Aerosol Liposome and Liposome-Drug Combinations for Medical Use and U.S. Patent Application Serial No. 08/933,254, entitled Small Particle Liposome Aerosols for Delivery of Anti-Cancer Drugs.
IPSCIO Record ID: 3957
IPSCIO Record ID: 179238
Liposome encapsulation is a process designed to entrap and deliver various useful materials. Prior to the development of the Novavax Technologies, the most commonly used technology, phospholipid liposome encapsulation, had a limited capacity to encapsulate anything other than materials that can be dissolved or suspended in water. Phospholipid liposomes are man-made, microscopic spheres that are usually formed through a multi-step process, which generally includes the mixing of water, organic solvents and phospholpids. Most phospholipid-based liposomes are produced from materials that are expensive and may require the use of potentially hazardous organic solvents. The standard, multi-step phospholipid manufacturing process yields small quantities of expensive, less stable vesicles with limited cargo capacity.
IPSCIO Record ID: 223861
IPSCIO Record ID: 314332
Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoamÂ® delivery system in order to develop and commercialize formulations of Liraglutide.
Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.
Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.